Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: Determinants of interruptions vary over time

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 882-890

  Cluze, C ^a,b,c   Rey, D ^a,b,c   Huiart, L ^a,d   BenDiane, M K ^a,b,c   Bouhnik, A D ^a,b,d   Berenger, C ^a,b,c   Carrieri, M P ^a,b,c   Giorgi, R ^b,e  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Adjuvant endocrine therapy; Breast neoplasm; Persistence; Prospective cohort study; Young

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RELAPSE; CANCER STAGING; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOCIAL SUPPORT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 81755181772     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr330     Document Type: Article

References (41)

1. Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-1792.
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
3. Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract 2010; 6: 243-246.
4. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-47.
5. Yood MU, Owusu C, Buist DS et al. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg 2008; 206: 66-75.
6. McCowan C, Shearer J, Donnan PT et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008; 99: 1763-1768.
7. Barron TI, Connolly R, Bennett K et al. Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007; 109: 832-839.
8. Lash TL, Fox MP, Westrup JL et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006; 99: 215-220.
9. Owusu C, Buist DS, Field TS et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008; 26: 549-555.
10. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59: 56-66.
11. Ziller V, Kalder M, Albert US et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009; 20: 431-436.
12. Hershman DL, Kushi LH, Shao T et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010; 28: 4120-4128.
13. Groves RM, Mathiowetz NA. Computer assisted telephone interviewing: effects on interviewers and respondents. Public Opin Q 1984; 48: 356-369.
14. Baumann C, Erpelding ML, Regat S et al. The WHOQOL-BREF questionnaire: French adult population norms for the physical health, psychological health and social relationship dimensions. Rev Epidemiol Sante Publique 2010; 58: 33-39.
15. Fuhrer R, Rouillon F. La version française de l'é chelle CES-D (Center for Epidemiologic Studies Depression Scale). Description and translation of the autoevaluation scale. Psychiatrie et Psychobiologie 1989; 4: 163-166.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
17. Cutuli B, Fourquet A, Luporsi E et al. [Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004]. Bull Cancer 2005; 92: 155-168.
18. Federation of French Cancer Centres (FNCLCC). Recommandations pour la pratique clinique de Saint-Paul-de-Vence: cancer du sein. Oncologie 2005; 7: 342-379.
19. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
20. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21: 602-606.
21. Wengstrom Y, Aapro M, Leto di Priolo S et al. Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study. Breast 2007; 16: 462-468.
22. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 555-567.
23. Fink AK, Gurwitz J, Rakowski W et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004; 22: 3309-3315.
24. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005; 59: 97-102.
25. Kirk MC, Hudis CA. Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 2008; 8: 155-161.
26. Thewes B, Meiser B, Duric VM et al. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 2005; 6: 581-588.
27. DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol 2004; 23: 207-218.
28. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652-661.
29. Knodel J, Kespichayawattana J, Saengtienchai C, Wiwatwanich S. The role of parents and family members in ART treatment adherence: evidence from Thailand. Res Aging 2010; 32: 19-39.
30. Sacajiu G, Raveis VH, Selwyn P. Patients and family care givers' experiences around highly active antiretroviral therapy (HAART). AIDS Care 2009; 21: 1528-1536.
31. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001; 19: 322-328.
32. Kahn KL, Schneider EC, Malin JL et al. Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 2007; 45: 431-439.
33. Pellegrini I, Sarradon-Eck A, Soussan PB et al. Women's perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients' point of view. Psychooncology 2010; 19: 472-479.
34. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
35. Fisher B, Dignam J, Wolmark N et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000.
36. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
37. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200-209.
38. Guth U, Huang DJ, Schotzau A et al. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 2008; 99: 428-433.
39. Kimmick G, Anderson R, Camacho F et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009; 27: 3445-3451.
40. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-574; discussion 575-577.
41. Gwadry-Sridhar FH, Manias E, Zhang Y et al. A framework for planning and critiquing medication compliance and persistence research using prospective study designs. Clin Ther 2009; 31: 421-435.